Daniel J. Levangie
Daniel J. Levangie is an experienced executive and corporate director with senior operating experience in the field of medical devices and invitro diagnostics.
Mr. Levangie is currently co-founder and Managing Partner of ATON Partners, a private investment firm, and Chairman, President and Chief Executive Officer of CereVasc, LLC, a medical device company. Until January 2017, Mr. Levangie was President of Insulet Drug Delivery Systems following his tenure as Lead Independent Director of Insulet Corporation (NASDAQ: PODD). Mr. Levangie also served as Chief Executive Officer of Dune Medical Devices, and Co-Founder and Managing Partner of Constitution Medical Investors, Inc., a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation (VTX: ROG) in July 2013.
Additionally, Mr. Levangie held a variety of executive management positions with Cytyc Corporation (acquired by Hologic Corporation, NASDAQ: HOLX), including Chief Executive Officer and President of Cytyc Health Corporation.
Prior to joining Cytyc Corporation in 1992, Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories (NYSE: ABT).
Mr. Levangie resides in Boston, MA with his wife Joan, and he is a member of the Board of Directors of Exact Sciences, Inc. (NASDAQ: EXAS), Dune Medical Devices, and CereVasc, LLC. Mr. Levangie, a graduate of the College of Pharmacy of Northeastern University in Boston, is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School of East Boston.